Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

ABSTRACT: Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an Institutional Review Board-approved clinical trial. Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high-throughput drug screening to discover effective treatment strategies. Analysis of tumor-d

SUBMITTER: Pauli C 

PROVIDER: S-EPMC5413423 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature